Evidence map›Paper›PMID 33382995›Full record

ArticleClinica chimica acta; international journal of clinical chemistry2021

Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood.

Harjit P Bhattoa, Etienne Cavalier, Richard Eastell, Annemieke C Heijboer, Niklas R Jørgensen, Konstantinos Makris, Candice Z Ulmer, John A Kanis, Cyrus Cooper, Stuart L Silverman and 2 more

Registry-linked trialOpen access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinica chimica acta; international journal of clinical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07242612 (Determination of Selective Bone Turnover Markers and Their Association With Treatment Efficacy in Primary Postmenopausal Osteoporotic Women), which is not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07242612 nacompletednot on this mapstarted 2025, after this paper: background citation

Determination of Selective Bone Turnover Markers and Their Association With Treatment Efficacy in Primary Postmenopausal Osteoporotic Women: A Randomized Control Trial

TypeinterventionalSponsorKhyber Medical University PeshawarRan2025 to 2026Enrolled40ConditionsOsteoporosis, Osteoporosis, PostmenopausalArmsAlendronate, Ibandronate, Risedronate, Teriparatide
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Bone turnover markers in the management of CKD-associated osteoporosis-a European consensus.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Advances in laboratory medicine · 2024
    Article
  13. Review
  14. Clinical use of bone markers: a challenge to variability.Advances in laboratory medicine · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Sclerostin: From Molecule to Clinical Biomarker.International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 8 countries.

Harjit P BhattoaDepartment of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Etienne CavalierDepartment of Clinical Chemistry, University of Liège, CHU de Liège, Domaine du Sart-Tilman, B-4000 Liège, Belgium.
Richard EastellMellanby Centre for Bone Research, University of Sheffield, Sheffield, UK.
Annemieke C HeijboerDepartment of Clinical Chemistry, Endocrine Laboratory, Amsterdam Gastroenterology & Metabolism, Vrije Universiteit Amsterdam and University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Niklas R JørgensenDepartment of Clinical Biochemistry, Rigshospitalet, DK-2600 Glostrup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Konstantinos MakrisClinical Biochemistry Department, KAT General Hospital, 14561 Athens, Greece; Laboratory for Research of the Musculoskeletal System "Th. Garofalidis", Medical School, University of Athens, Athens, Greece.
Candice Z UlmerClinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
John A KanisCentre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK and Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Cyrus CooperThe MRC Epidemiology Resource Centre, Southampton General Hospital, University of Southampton, Southampton, UK.
Stuart L SilvermanCedars-Sinai Medical Center and UCLA School of Medicine, Beverly Hills, CA, USA.
Samuel D VasikaranPathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia. Electronic address: samuel.vasikaran@health.wa.gov.au.
IFCC-IOF Committee for Bone Metabolism
Amsterdam University Medical Centers · NLAustralian Catholic University · AUCedars-Sinai Medical Center · USCenters for Disease Control and Prevention · USFiona Stanley Hospital · AUNational and Kapodistrian University of Athens · GRSouthampton General Hospital · GBUniversity of Copenhagen · DKUniversity of Debrecen · HUUniversity of Liège · BEUniversity of Sheffield · GB

Funding

Department of Health 10/33/04Intramural CDC HHS CC999999Medical Research Council G0400491Medical Research Council MC_PC_21000Medical Research Council MC_ST_U13058Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1015Medical Research Council MC_UU_12011/1Medical Research Council MC_UU_12011/2Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood have been designated as reference bone turnover markers in osteoporosis by the International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). The IFCC Committee on Bone Metabolism (C-BM) has examined current commercial assays and performed a multicentre study to examine the agreement between assays for PINP and β-CTX in serum and plasma. The results of these studies will inform our work towards the harmonization of PINP assays and the standardization of β-CTX assays in blood, with the development of common calibrators and reference measurement procedures in collaboration with the reagent manufacturing industry. Successful achievement of these goals will help develop universally acceptable practice guidelines for the management of osteoporosis with the inclusion of common reference intervals and treatment targets for PINP and β-CTX.

Indexed as

Peptide FragmentsProcollagenBiomarkersBone RemodelingCollagen Type IHumansPeptidesBiomarkersCollagen Type IPeptide FragmentsPeptidesProcollagenBone formationBone resorptionBone turnover markersC-terminal telopeptide of type I collagenHarmonizationPINPProcollagen type I N-propeptideStandardizationβ-CTX

Identifiers

PMID33382995
PMCPMC8033406
OpenAlexW3115646307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.